Pneumococcal Disease
59
7
11
46
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
29 trials with published results (49%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 59 trials
100.0%
+13.5% vs benchmark
56%
33 trials in Phase 3/4
63%
29 of 46 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 46 completed trials
Clinical Trials (59)
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan
Serum Collection Study for Assay Development
Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)